iNovacia develops its compound collection


Published on

Press release

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

iNovacia develops its compound collection

  1. 1. iNovaciaPress release Stockholm 2011-06-28iNovacia Further Develops its Compound CollectioniNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMXStockholm First North, KAN), today announced the addition of over 20,000 novel compounds to itssmall-molecule screening collection. This is in line with the continuous development to maintain aworld leading library offered to its international pharma and biotech clients.The new and novel compounds have been developed in an exclusive joint effort together withAsinex Ltd in Moscow. Before the addition the iNovacia screening collection consisted ofapproximately 280,000 compounds selected based on diversity, novelty and lead-likenesses. “Ourscreening collection is now reaching 300,000 compounds. The size and the chemical diversity of thelibrary is well adapted for vigorous screening to develop new drug candidates. The key is to combinediversity and novelty with compounds of high purity and which are amenable for rapid optimization”says Dr. Martin Norin, Chief Operating Officer at iNovacia. He continues: “Our chemistscontinuously synthesize novel scaffolds to enrich our collection even further. Typically, we haveabout 50-100 compounds per scaffold in our library and we have an excellent track-record indelivering viable hit and lead series to our clients”.Earlier this year, iNovacia introduced new filters identifying e.g. Pan Assay InterferenceCompounds (PAINS), promiscuous compounds that may appear as frequent false positive hits inscreening campaigns, and the replacement of such compounds in the collection. This is also in linewith iNovacia’s strategy to maintain a screening collection of the very highest quality.About iNovaciaiNovacia provides high-throughput screening, fragment-based screening and other drug discoveryservices to translate targets into validated leads for pharmaceutical and biotech companies.Enabled by a chemical library of highest international standard, unique biophysical tools forcharacterization of mode-of-action and SAR, iNovacia can minimize the technical risk and optimizelead-time and quality of drug discovery projects. iNovacia is a wholly owned subsidiary of KanceraAB (Nasdaq OMX Stockholm First North, KAN).About Kancera AB (publ)Kancera develops the basis for new therapeutics, starting with new treatment concepts and endingwith drug candidate. Kancera is currently running two projects, one to develop a treatmentleukemia and one project targeting cancer’s ability to generate energy in order to survive. Kanceraalso develops novel cancer models that provide clinically relevant information on drug candidatesbefore clinical trials are started. Kancera’s operations are run at Pharmacia’s former premises atKungsholmen in Stockholm, Sweden. Kancera employs 20 people. The share is traded atNASDAQ OMX First North. The number of shareholders is approximately 1200. Remium AB is theCertified Advisor to Kancera.For further information, please contact:Thomas Olin, CEO+46 735 20 40 01 or thomas.olin@inovacia.seiNovacia ABLindhagensgatan 133 SE 112 51